Cilgavimab |
| カタログ番号GC72412 |
Cilgavimab（AZD-1061；COV 2-2130）はヒト重症急性呼吸器症候群コロナウイルス2型を中和するモノクローナル抗体であり、Tixagevimabとモノクローナル抗体の組み合わせAZD 7442を構成することができる。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2420563-99-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cilgavimab and Tixagevimab simultaneously bind to distinct, nonoverlapping epitopes of the SARS-CoV-2 spike-protein (S) receptor-binding domain to potently neutralize the virus[1].
Cilgavimab exhibits potent monoclonal antibody neutralization activity, and human ACE2-blocking activity, with IC50s of 10-150 ng/mL, and shows binding ability to either trimeric S2Pecto protein or monomeric SRBD with IC50s of 0.1-10 ng/mL[2].
Cilgavimab (200 μg/mouse; i.p.; before SARS-CoV-2 injection) protects mice from weight loss and reduces the viral burden and levels of inflammation in the lungs[2].
References:
[1]. Levin MJ, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200.
[2]. Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *